TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall response rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial remission (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency score of spontaneous bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: degree of straining on defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Constipation Quality of Life Scale post‐test scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean ICU stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of POST at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fixation effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Spo2 during physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms of hypoxia during activity
Endpoint domain: Adverse events/effects
Primary endpoint: arrhythmic mortality
Endpoint domain: Mortality/survival
Primary endpoint: less skin darkening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sun protective behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SUI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life impact due to incontinence and urogenital distress
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cardiotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial function test (EFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bayley‐III cognitive scale raw score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incident knee osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Need for exchange transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in the left atrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in ptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: endline eTDP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast milk thiamine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant eTDP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum concentration of cTnI and CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total breast cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: Invasive breast cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of women with abnormal mammograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of rhinorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of sneezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative grade ≥ 3 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of urine culture testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antimicrobial prescribing for UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Concentrations (GMCs) of anti-rotavirus IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: suppression of OUCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: suppression of K
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to fatal myocardial infarctions (MIs)
Endpoint domain: Mortality/survival
Primary endpoint: Quality score of reporting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Outcome measures on body function and structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of activity and/or participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasma GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Occurrence of fDGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of prolonged fDGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Faecal score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Painful defecation and abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postoperative Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: homologous blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative mean pain VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ponezumab
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Aβ species concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological peri-implant soft tissue features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased creatinine clearance
Endpoint domain: Adverse events/effects
Primary endpoint: Risk for diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extent of oxycodone absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of oxycodone absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of ibuprofen absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative central body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soluble E‐selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: beta‐thromboglobulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ranking of computer usefulness in anesthesia care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reaction speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful significant improvement of SNOT-20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average arterial attenuation value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean signal-to-noise ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteinuria and eGFR < 60 ml/min
Endpoint domain: Mortality/survival
Primary endpoint: Unmonitored renal function
Endpoint domain: Adverse events/effects
Primary endpoint: 25(OH)D levels (nanomoles per liter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of incident depressive episodes
Endpoint domain: Mortality/survival
Primary endpoint: Self-reported depressive symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dyspepsia-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total plasma carotenoids concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma total homocysteine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kaplan‐Meier survivorship free from revision
Endpoint domain: Mortality/survival
Primary endpoint: Number of efforts after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liking for Gastrotuss(®)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IIEF-EF domain score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of soy foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Consumption of milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Increased exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D/exposure to sunlight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immediate continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of overweight/obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transition to a healthy weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentrations of IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-reported absenteeism from work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Global mean field amplitudes of TMS-evoked responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Polyp numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative adduct labeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plaque levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised Oral Assessment Guide scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time with intragastric pH >3.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of time with intragastric pH >3.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: average IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily energy intake maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Material fracture and retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bladder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UDI scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: non-OD death rate
Endpoint domain: Mortality/survival
Primary endpoint: Deceleration capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceleration capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction after 1 year of therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Indebtedness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinically significant change in CAPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total hemoglobin loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: requirement for transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: side-effect profiles
Endpoint domain: Adverse events/effects
Primary endpoint: tolerability profiles
Endpoint domain: Adverse events/effects
Primary endpoint: CT value of pulmonary artery images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CNR of pulmonary artery images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary score of pulmonary artery images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of postoperative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reversal rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in key ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate of SVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pad-free status at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative major adverse clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: medication side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Peripapillary retinal nerve fiber layer (RNFL) thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Threshold sensitivities evaluated with SAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recovery rate of facial nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time needed for significant recovery (Ti)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time point after which no further improvement (Tf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incremental QALY gain
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: KOOS quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Full active knee extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PE and DVT
Endpoint domain: Mortality/survival
Primary endpoint: Atrioventricular block resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventricular tachycardia occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction on the Oswestry scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the neck disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction on the visual analogue scale for low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal resistance in gastric ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Consumption of postoperative rescued sufentanil
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: long-term outcome after TBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSP scale score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-12 Physical scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboxane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bleeding times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: belief in strategies to help patients change psychosocial situation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: confidence in making appropriate referrals for psychosocial problems
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: belief in access to information for managing psychosocial issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appetite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rumination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: negative coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: in-segment late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: binary in-segment restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target vessel failure (TVF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of the PRISM Chagas assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the PRISM Chagas assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative wake-up times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative wake-up times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of intra- and postoperative arousals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster recovery of neuropsychiatric function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: proportion of patients with anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean minimum % post-saline FEV1 at 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean minimum % post-saline FEV1 in early response (0-2 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean minimum % post-saline FEV1 in late phase response (4 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Satisfaction with life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Unmet needs with medication and routine health care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent retained score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: recognition biases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of cases with level I evidence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: area-under-the-curve for impaired PET hyperaemic myocardial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain reduction in the spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 4 week survival rate
Endpoint domain: Mortality/survival
Primary endpoint: HBV DNA negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful treatment by nonoperative approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plaque and bleeding scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: probing depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Asymptomatic relapse detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacteriologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes